BriaCell Therapeutics Corp. (NASDAQ:BCTX) Expected to Announce Earnings of -$0.18 Per Share

Brokerages forecast that BriaCell Therapeutics Corp. (NASDAQ:BCTX) will report earnings per share (EPS) of ($0.18) for the current quarter, Zacks reports. Zero analysts have issued estimates for BriaCell Therapeutics’ earnings. BriaCell Therapeutics posted earnings per share of ($0.41) in the same quarter last year, which indicates a positive year over year growth rate of 56.1%. The company is expected to issue its next quarterly earnings results on Wednesday, March 30th.

According to Zacks, analysts expect that BriaCell Therapeutics will report full year earnings of ($0.80) per share for the current financial year. For the next fiscal year, analysts forecast that the company will post earnings of ($1.09) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover BriaCell Therapeutics.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings data on Tuesday, December 14th. The company reported ($0.15) EPS for the quarter.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in shares of BriaCell Therapeutics during the 2nd quarter valued at about $337,000. Armistice Capital LLC purchased a new stake in shares of BriaCell Therapeutics during the 2nd quarter worth about $3,040,000. Redmond Asset Management LLC grew its holdings in shares of BriaCell Therapeutics by 3.7% during the 3rd quarter. Redmond Asset Management LLC now owns 136,593 shares of the company’s stock worth $1,106,000 after purchasing an additional 4,862 shares during the period. Kepos Capital LP purchased a new stake in shares of BriaCell Therapeutics during the 2nd quarter worth about $2,665,000. Finally, Total Clarity Wealth Management Inc. purchased a new stake in shares of BriaCell Therapeutics during the 3rd quarter worth about $93,000. 29.44% of the stock is owned by institutional investors.

NASDAQ BCTX opened at $8.45 on Friday. BriaCell Therapeutics has a 12 month low of $2.81 and a 12 month high of $12.47. The company has a 50-day moving average of $9.11 and a 200-day moving average of $7.38.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.

Further Reading: How do CD ladders protect against rising interest rates?

Get a free copy of the Zacks research report on BriaCell Therapeutics (BCTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.